TheraRadar
← Back
Data updated: Mar 29, 2026

QILU

OncologyCardiovascularInfectious Disease
Generics

QILU is a generic drug manufacturer focused on Oncology, Cardiovascular, Infectious Disease.

2016
Since
17
Drugs
-
Trials
123
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

MEROPENEM 2026-02-17
Labeling
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
LENALIDOMIDE 2026-02-02
OLANZAPINE 2026-01-23
OLANZAPINE 2026-01-22
Labeling
CYCLOSPORINE 2026-01-21
MIRABEGRON 2026-01-20
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 66%
4 drugs Phase 3: 17 Phase 2: 10 Phase 1: 27
Cardiovascular 11%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 3
Infectious Disease 9%
1 drugs Phase 3: 3 Phase 1: 2
Dermatology 7%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 3
Immunology 7%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Immunology, Oncology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular